DEPO-MEDROL CUM LIDOCAIN

This brand name is authorized in Finland

Active ingredients

The drug DEPO-MEDROL CUM LIDOCAIN contains a combination of these active pharmaceutical ingredients (APIs):

1 Methylprednisolone
UNII 43502P7F0P - METHYLPREDNISOLONE ACETATE

Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system.

Read about Methylprednisolone
2 Lidocaine
UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.

Read about Lidocaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
H02BX01 Methylprednisolone, combinations H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS → H02BX Corticosteroids for systemic use, combinations
Discover more medicines within H02BX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: FI Lรครคkealan turvallisuus- ja kehittรคmiskeskus Identifier(s): 134643, 136085

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.